Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
January 2020
-
Media ReleaseNovartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiranOver 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL…
-
Key ReleaseNovartis completes tender offer for all outstanding shares of The Medicines CompanyBasel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger…
December 2019
-
Media ReleaseAveXis Community Statement on Global Managed Access Program for AVXS-101Dear SMA Community, Since its U.S. approval, AveXis has had increasing demand from families outside of the U.S. for access to AVXS-101. While we are pursuing registration in close to three dozen…
-
Parental Leave at Novartis: Michael's story
At Novartis, we celebrate life and recognize moments that matter. Michael Wieser shares his experience of parental leave and becoming a father of two.
-
Key ReleaseNovartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthmaPooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across…
-
Media ReleaseNovartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMDIn two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-…
-
Media ReleaseNovartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30…
-
Media ReleaseNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world settingEfficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3 Fewer known CAR-T cell therapy…
-
Featured NewsUncovering profound and under-reported effects on people living with sickle cell disease
Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.
-
Media ReleaseNovartis global survey uncovers profound and often under-reported effects on sickle cell disease patientsFindings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell disease and a pattern of not seeking care despite potentially life-…
-
A decades-long journey in blood cancer research
Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
-
Media ReleaseNovartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapyOnce-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak…
Pagination
- ‹ Previous page
- 1
- …
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- …
- 152
- › Next page